Home » Authors » Randy Osborne

Articles by Randy Osborne

Tengion Series B Gets $50M For Autologous-Bladder Work

June 28, 2006

By Randy Osborne

Cypress, Organon Mull Future Of Mirtazapine Collaboration

June 28, 2006

By Randy Osborne

Metabolex's Multi-Part Deal With Ortho: $548M Potential

June 27, 2006

By Randy Osborne

Nastech, Amylin Nasal Byetta Partnership Has $89M Ceiling

June 27, 2006

By Randy Osborne

HGS' $165M Anthrax Score Should Boost Albuferon Bid

June 26, 2006

By Randy Osborne

Alnylam, Sirna Argue Over Win In European RNAi Patent Fight

June 26, 2006

By Randy Osborne

XenoPort Offering: $76.5M For Transported Prodrugs

June 23, 2006

By Randy Osborne

Sucampo, BioVex Line Up To Take Shot At Public Markets

June 21, 2006

By Randy Osborne

Nutra Pharma Plans Buyout Of ReceptoPharm In Shares

June 20, 2006

By Randy Osborne

Sangamo Stock Sale Raises $20M For Zinc-Finger Efforts

June 19, 2006

By Randy Osborne

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.